Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level

Daniela I. Batovska, Dong Hoon Kim, Shinya Mitsuhashi, Yoon Sun Cho, Ho Jeong Kwon, Makoto Ubukata

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARγ agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC50 values of 1, 0.9 and 0.5 μM, and cell proliferation at concentrations of 2, 1.5 and 1 μM, respectively.

Original languageEnglish
Pages (from-to)2623-2631
Number of pages9
JournalBioscience, Biotechnology and Biochemistry
Volume72
Issue number10
DOIs
Publication statusPublished - 2008 Nov 5

Fingerprint

Mycophenolic Acid
Hydroxamic Acids
Histone Deacetylases
Histone Deacetylase Inhibitors
Derivatives
IMP Dehydrogenase
Metals
Binding Sites
Peroxisome Proliferator-Activated Receptors
T-cells
Cell proliferation
Immunosuppressive Agents
Cutaneous T-Cell Lymphoma
Multiple Myeloma
Inhibitory Concentration 50
Transplantation
Cell Proliferation
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Analytical Chemistry
  • Biochemistry
  • Applied Microbiology and Biotechnology
  • Molecular Biology
  • Organic Chemistry

Cite this

Batovska, Daniela I. ; Kim, Dong Hoon ; Mitsuhashi, Shinya ; Cho, Yoon Sun ; Kwon, Ho Jeong ; Ubukata, Makoto. / Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level. In: Bioscience, Biotechnology and Biochemistry. 2008 ; Vol. 72, No. 10. pp. 2623-2631.
@article{9dda16b4e1a54a0f841f1b96b11d94b4,
title = "Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level",
abstract = "Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARγ agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC50 values of 1, 0.9 and 0.5 μM, and cell proliferation at concentrations of 2, 1.5 and 1 μM, respectively.",
author = "Batovska, {Daniela I.} and Kim, {Dong Hoon} and Shinya Mitsuhashi and Cho, {Yoon Sun} and Kwon, {Ho Jeong} and Makoto Ubukata",
year = "2008",
month = "11",
day = "5",
doi = "10.1271/bbb.80303",
language = "English",
volume = "72",
pages = "2623--2631",
journal = "Bioscience, Biotechnology and Biochemistry",
issn = "0916-8451",
publisher = "Japan Society for Bioscience Biotechnology and Agrochemistry",
number = "10",

}

Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level. / Batovska, Daniela I.; Kim, Dong Hoon; Mitsuhashi, Shinya; Cho, Yoon Sun; Kwon, Ho Jeong; Ubukata, Makoto.

In: Bioscience, Biotechnology and Biochemistry, Vol. 72, No. 10, 05.11.2008, p. 2623-2631.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level

AU - Batovska, Daniela I.

AU - Kim, Dong Hoon

AU - Mitsuhashi, Shinya

AU - Cho, Yoon Sun

AU - Kwon, Ho Jeong

AU - Ubukata, Makoto

PY - 2008/11/5

Y1 - 2008/11/5

N2 - Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARγ agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC50 values of 1, 0.9 and 0.5 μM, and cell proliferation at concentrations of 2, 1.5 and 1 μM, respectively.

AB - Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARγ agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC50 values of 1, 0.9 and 0.5 μM, and cell proliferation at concentrations of 2, 1.5 and 1 μM, respectively.

UR - http://www.scopus.com/inward/record.url?scp=55049101683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55049101683&partnerID=8YFLogxK

U2 - 10.1271/bbb.80303

DO - 10.1271/bbb.80303

M3 - Article

C2 - 18838793

AN - SCOPUS:55049101683

VL - 72

SP - 2623

EP - 2631

JO - Bioscience, Biotechnology and Biochemistry

JF - Bioscience, Biotechnology and Biochemistry

SN - 0916-8451

IS - 10

ER -